Eli Lilly and Company (SWX:LLY)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
630.00
+15.00 (2.44%)
At close: Oct 20, 2025
2.44%
Market Cap574.73B
Revenue (ttm)42.36B
Net Income (ttm)10.97B
Shares Outn/a
EPS (ttm)12.16
PE Ratio52.37
Forward PE29.03
Dividend4.98 (0.79%)
Ex-Dividend DateAug 15, 2025
Volumen/a
Average Volume3
Openn/a
Previous Close615.00
Day's Rangen/a
52-Week Range538.92 - 805.00
Beta0.33
RSI48.58
Earnings DateOct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Drug Manufacturers - General
Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange SIX Swiss Exchange
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk and J&J in focus

Get the latest healthcare stock updates, key pharma deals, and major legal developments impacting the S&P 500.

2 days ago - Seeking Alpha

Our Top 10 High Growth Dividend Stocks - October 2025

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...

3 days ago - Seeking Alpha

President Trump targets $150 MFN price for GLP-1s

Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1...

3 days ago - CNBC Television

President Trump targets $150 MFN price for GLP-1s

Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1...

3 days ago - CNBC

Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s

Eli Lilly and Novo Nordisk shares dropped after President Donald Trump said he wants a $150 price tag for GLP-1s.

4 days ago - CNBC

3 Price Catalysts For Eli Lilly

4 days ago - Seeking Alpha

Eli Lilly (LLY) Shares Drop Due to Recent Voucher Snub and Competitive Pricing Pressures

Eli Lilly (LLY) Shares Drop Due to Recent Voucher Snub and Competitive Pricing Pressures

4 days ago - GuruFocus

Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks

Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Li...

4 days ago - Investopedia

Trump Pledges To Cut Obesity Drug Prices. Novo Nordisk, Eli Lilly Stocks Dive.

Novo Nordisk and Eli Lilly stocks slumped Friday after President Donald Trump said he would cut the price of weight-loss drugs.

4 days ago - Investor's Business Daily

Is Trump Going to Kill the GLP-1 Cash Cow?

The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive revenue streams for Novo Nordisk (NYSE:NVO) and ...

4 days ago - 24/7 Wall street

Eli Lilly Shares Are Trading Lower Friday: What's Going On?

Eli Lilly shares are trading lower Friday, ... Full story available on Benzinga.com

4 days ago - Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades . His promise to cut the cost of Novo Nordisk A/S (NYSE: NVO) blockbuster drug Ozempic from around $1,300...

4 days ago - Benzinga

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...

4 days ago - Benzinga

Lilly's Verzenio Extends Survival In High-Risk Early Breast Cancer With Two Years Of Treatment

(RTTNews) - Eli Lilly and Company (LLY) on Friday reported that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% compared with endocrine therapy alone in patien...

4 days ago - Nasdaq

Eli Lilly (LLY) Reports Promising Results from Phase 3 monarchE Trial

Eli Lilly (LLY) Reports Promising Results from Phase 3 monarchE Trial

4 days ago - GuruFocus

Eli Lilly Sets Ambitious Sustainability Goals Despite Headwinds

Eli Lilly's prescription for growth and sustainability includes a strong drug pipeline, revenue growth and energy investments.

4 days ago - Investor's Business Daily

Stock Market Today: Dow Wavers Amid Bank Fears; Eli Lilly, Novo Sell Off On Trump Comments (Live Coverage)

Stock Market Today: The Dow Jones index dropped Friday amid bank fears. Eli Lilly and Novo Nordisk tumbled on Trump comments. The post Stock Market Today: Dow Wavers Amid Bank Fears; Eli Lilly, Novo S...

4 days ago - Investor's Business Daily

Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug

Eli Lilly said Friday a combination using Verzenio reduced the risk of death by nearly 16% over two years for breast cancer patients.

4 days ago - Investor's Business Daily

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the P...

4 days ago - PRNewsWire

Marketers on the Move: Hires and Departures at Cadillac, Eli Lilly, and More

A weekly roundup of the biggest U.S. and global brand leadership appointments.

4 days ago - Adweek

Eli Lilly, Novo Nordisk Stocks Drop After Trump's Ozempic Price Comment. What to Know.

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”

4 days ago - Barrons

Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower

Stock index futures slump as concerns on health of banks rattle sentiments. Novo Nordisk, Eli Lilly slide after Trump pledges 'much lower' Ozempic price. Ford to recall nearly 625K vehicles.

4 days ago - Seeking Alpha

Eli Lilly, Novo Nordisk Tumbles After Trump Says Weight-Loss Drugs Are 'Too Expensive'

Eli Lilly, Novo Nordisk Tumbles After Trump Says Weight-Loss Drugs Are 'Too Expensive'

4 days ago - GuruFocus